News Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
24.02 ^USD	+12.98%		+5.44%	-11.76%

May. 07	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	MT
May. 07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference	May. 08	GL
Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	May. 07	MT
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results	May. 07	GL
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	Mar. 26	MT
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	Mar. 26	GL
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	Mar. 26	AQ
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	Mar. 26	CI
Transcript : Beam Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:35 PM	Mar. 13
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	Feb. 28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	Feb. 28	MT
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	Feb. 28	GL
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	Feb. 28	AQ
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	Feb. 27	DJ
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	Feb. 27	MT
Beam Therapeutics Shares Jump on Surprise Q4 Profit	Feb. 27	MT
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	Feb. 27	MT
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	Feb. 27	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST